The central role of Epstein-Barr virus in causing multiple sclerosis is examined to understand how it triggers the disease and presents new opportunities for treatment “Evidence is mounting that ...

The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' therapy to treat patients with a ...

offering comprehensive insights into the Epstein Barr Virus revenue trends, prevalence, and treatment landscape. The report delves into key Epstein Barr Virus statistics, highlighting the current ...

The FDA has issued a complete response letter to the biologics license application seeking the approval of tabelecleucel for ...

Atara Biotherapeutics said the U.S. Food and Drug Administration placed a clinical hold on its active investigational new drug applications. The biotechnology company said the FDA put a hold on its ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...

The FDA didn't approve the therapy in EBV-positive post-transplant lymphoproliferative disease due to findings at a third-party manufacturing facility.

Nat Clin Pract Neurol. 2007;3(2):82-94. EBV establishes latency in B lymphocytes, which adopt restricted patterns of EBV gene expression. EBV latency has been classified into three types ...

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) tumbled 51% after the company disclosed receiving a Complete Response ...

Tabelecleucel, an allogeneic, EBV-specific T-cell immunotherapy, works by targeting and eliminating EBV-infected cells.